Open AccessProstate Cancer Theranostics Targeting Gastrin-Releasing Peptide Receptors
Author(s) -
Lucia Baratto,
Hossein Jadvar,
Andrei Iagaru
Publication year - 2017
Publication title -
molecular imaging and biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.846
H-Index - 68
eISSN - 1860-2002
pISSN - 1536-1632
DOI - 10.1007/s11307-017-1151-1
Subject(s) - bombesin , prostate cancer , medicine , prostate , gastrin releasing peptide , cancer , gastrin , receptor , cancer research , in vivo , pancreas , oncology , biology , neuropeptide , microbiology and biotechnology , secretion
Gastrin-releasing peptide receptors (GRPRs), part of the bombesin (BBN) family, are aberrantly overexpressed in many cancers, including those of the breast, prostate, pancreas, and lung, and therefore present an attractive target for cancer diagnosis and therapy. Different bombesin analogs have been radiolabeled and used for imaging diagnosis, staging, evaluation of biochemical recurrence, and assessment of metastatic disease in patients with prostate cancer. Recently, interest has shifted from BBN-like receptor agonists to antagonists, because the latter does not induce adverse effects and demonstrate superior in vivo pharmacokinetics. We review the preclinical and clinical literatures on the use of GRPRs as targets for imaging and therapy of prostate cancer, with a focus on the newer developments and theranostic potential of GRPR peptides.